TEL AVIV, Israel—EyeYon Medical, a start-up developing ophthalmic products for vision-threatening conditions, announced the completion of $25 million in a Series C funding. This latest round brings the total amount of capital raised by the company to $36 million, according to EyeYon, based here. The new capital will be used to expand the clinical trials of EyeYon Medical's flagship product, the EndoArt, a synthetic implant which enables doctors to treat chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue.

With nearly 13 million patients on the waiting list for corneal transplant, the EndoArt was created in an effort to ease global shortages of corneal donations, EyeYon said. Clinical trials, which are already underway in selected medical centers across Europe (IVRC in Heidelberg, Instituto de Microcirugia Ocular (IMO) in Barcelona, and AMC in Amsterdam) and in Israel (Soroka Medical Center, Rambam Health Care Campus, Tel Aviv Sourasky Medical Center and Barzilai Medical Center) have demonstrated the safety and efficacy of EyeYon Medical's technology, the company said.

Following the new investments, EyeYon Medical plans to expand its clinical trials with the aim to receive regulatory approval in the U.S., China and Europe and leverage the company's extensive professional network and the high demand for the product.

The funding round was led by the CR-CP Life Science Fund. Other participants included Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund.

EyeYon Medical was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera MD, and Dr. Arie Marcovich, MD., and develops advanced technology to treat acute ophthalmic problems.